On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.
|Title||Open label evaluation of cannabidiol in dystonic movement disorders.|
|Author(s)||Consroe P, Sandyk R, Snider SR|
|Journal, Volume, Issue||International Journal of Neuroscience 1986;30(4):277-282|
|Major outcome(s)||20-50% improvement of dystonia; deterioration of tremor and hypokinesia in 2 patients with Parkinson's disease|
|Indication||Dystonia; Parkinson's disease||Abstract|
Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.
|Dose(s)||100-600 mg per day|
|Participants||5 patients with dystonia|
|Type of publication|
|Address of author(s)||Department of Pharmacology/Toxicology, University of Arizona Health Sciences Center, Tucson, USA|